A drug at the heart of Johnson & Johnson's $3 billion takeover of Halda last year, JNJ-6143, has shown promise in an ...
On Oct 23, China’s deputy permanent representative to the UN, Sun Lei, at a UN General Assembly Sixth Committee meeting, ...
Sofetabart mipitecan (Sofe-M) in combination with bevacizumab demonstrated a 79% confirmed objective response rate and 100% disease control rate, with similar activity ...
Sofetabart mipitecan (Sofe-M) in combination with bevacizumab demonstrated a 79% confirmed objective response rate and 100% ...
PANKU-Breast01: Iza-bren cut progression or death risk by 59% vs chemotherapy in pretreated HR+/HER2− advanced breast cancer.
BioNTech enters a clinical trial collaboration with Gilead Sciences with the aim of improving outcomes in patients with PD-L1 low or negative triple-negative breast cancerThe global Phase 3 ROSETTA Br ...
BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced a clinical trial collaboration and supply agreement with Gilead ...
BioNTech SE announced a clinical trial collaboration and supply agreement with Gilead Sciences Inc. (?Gilead?) to evaluate pumitamig in combination with the TROP2-directed antibody-drug conjugate ...
Seven weeks after six opposition parties prepared five documents to guide cooperation ahead of the 2027 elections, consultations with presidential candidates have advanced, but the documents' status ...
Rakovina has advanced the program from target specification through lead generation and five cycles of iterative lead optimization in approximately two years, using Variational AI’s Enki™ generative ...
Ivonescimab was invented by Akeso Inc. (HKEX Code: 9926.HK) and is currently utilized in multiple Phase III clinical trials. Over 5,000 patients have been treated with ivonescimab in clinical studies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results